Quick Recap
Toxicology System, Protocol 2/8.
1. Presentation
Opioid toxidrome: lethargy, hypercarbic respiratory failure (hypoventilation progressing to apnea), miosis (pinpoint pupils — the classic exam clue), decreased GI motility, hypotension (from histamine release, more common with certain agents like meperidine), hypothermia. ABG may show elevated PaCO2 and hypoxemia in severe intoxication. Noncardiogenic pulmonary edema may occur — both from the opioid itself and, paradoxically, sometimes precipitated by naloxone reversal (rapid catecholamine surge).
Seizures may occur from accumulation of neurotoxic metabolites of SPECIFIC opioids — meperidine, propoxyphene, and tramadol carry this risk more than typical mu-agonists.
Co-ingestant consideration: acetaminophen or aspirin toxicity may complicate the presentation when combination analgesics (e.g., acetaminophen-opioid combination products) have been ingested — actively screen for these given the very different, time-sensitive management each requires (see acetaminophen/NAC principles in the Acute Liver Failure protocol, GI & Hepatology System).
Diagnosis is CLINICAL — drug screens may NOT detect some opioid medications specifically (fentanyl, methadone), so a negative urine toxicology screen does NOT exclude opioid toxicity. Patients with a toxidrome consistent with opioid toxicity should be treated empirically REGARDLESS of toxicology screening results.
2. Immediate Stabilization (ABCDE)
Airway/Breathing — the central intervention:
- Management is primarily directed at ensuring airway protection and adequate ventilation through EARLY use of naloxone
- Naloxone dosing: 0.04-2.0mg IV every 2 minutes titrated to effect, up to a maximum of 10mg; also available IM or intranasal routes
- The desired endpoint is MAINTENANCE OF AIRWAY PROTECTION AND ADEQUATE VENTILATION — NOT full reversal of sedation/consciousness — titrate to the minimum dose achieving adequate respiratory status, not to a fully awake/alert patient
- Doses above this target effect may precipitate acute opioid withdrawal, agitation, and pain — an important reason to start low and titrate carefully rather than giving a large empiric bolus reflexively, particularly in patients with chronic opioid dependence
- Naloxone should be viewed as an agent to PREVENT intubation, NOT for routine use AFTER mechanical ventilation has already been initiated — once a definitive airway is secured, the urgency/rationale for naloxone changes (though it may still have a role in facilitating extubation once appropriate)
Checklist:
3. Duration Mismatch — The Central Monitoring Principle
Naloxone's duration of action is 1-2 HOURS, which may be SHORTER than the activity of the causative opioid — this mandates patient monitoring for SEVERAL HOURS after apparent reversal, since re-sedation/re-respiratory-depression can occur once naloxone wears off while the longer-acting opioid is still active. Intoxication with LONG-ACTING opioids (methadone, extended-release formulations, fentanyl patches) may require REPEATED naloxone doses given this duration mismatch.
Continuous naloxone infusion: can be used for patients requiring repeated dosing — typically dosed at two-thirds of the effective bolus dose per hour; dosing assistance from a pharmacist or toxicologist is recommended given the need for individualized titration.
A need for continuous naloxone infusion is itself an ICU admission criterion (see Organophosphate Poisoning protocol Section 5 for the shared general poisoning ICU admission list).
4. Special Considerations by Agent
Fentanyl and illicitly-manufactured fentanyl analogs: increasingly the dominant driver of opioid overdose in many regions; may require HIGHER or REPEATED naloxone doses relative to traditional opioids given potency, and the urine toxicology screen limitation (Section 1) applies specifically here — do not rely on a negative fentanyl-non-detecting standard opioid screen.
Methadone: very long half-life — particularly prone to the duration-mismatch re-sedation problem; strongly consider extended monitoring or a naloxone infusion rather than single-dose reversal alone.
Meperidine, propoxyphene, tramadol: seizure risk from neurotoxic metabolites — have benzodiazepines available; naloxone reversal does not eliminate this seizure risk since it is metabolite-driven, not purely receptor-mediated.
Loperamide (an over-the-counter antidiarrheal opioid agonist, subject to misuse at supratherapeutic doses for euphoric/withdrawal-management effect): can cause significant cardiac conduction abnormalities (QT prolongation, wide-complex arrhythmia) at high doses, in addition to typical opioid toxicity — obtain an ECG and consider IV sodium bicarbonate for wide-complex tachycardia per the general toxicology approach to sodium-channel-blockade-type presentations.
5. Investigations
ABG (hypercarbia/hypoxemia assessment), ECG (arrhythmia screening, especially with loperamide or other atypical agent suspicion), acetaminophen and salicylate levels (co-ingestant screening with combination products), CXR if pulmonary edema/aspiration suspected, urine toxicology screen (understanding its limitations for fentanyl/methadone, per Section 1) and blood samples held for further analysis if diagnostic uncertainty exists.
6. Organ Support
Naloxone titrated to effect (bolus or infusion per duration-mismatch considerations); mechanical ventilation for refractory respiratory failure or airway protection needs beyond what naloxone can safely achieve; standard ICU supportive care; benzodiazepines for seizures if agent-specific risk present; treat co-ingestant toxicity (e.g., NAC for acetaminophen) per its own protocol.
7. Consultation Matrix
Consultation | Trigger | Timing |
Toxicology/Poison Control | Complex/refractory cases, unclear co-ingestants, need for naloxone infusion dosing guidance | As needed |
Psychiatry/Addiction Medicine | All opioid overdose, particularly intentional or recurrent presentations | Once medically stabilized |
8. Monitoring Framework
Extended respiratory status monitoring for SEVERAL HOURS post-naloxone reversal (given the duration mismatch), continuous pulse oximetry/capnography where available, repeat naloxone dosing as needed, ECG monitoring if an atypical/cardiotoxic agent (loperamide) is suspected, watch for precipitated withdrawal symptoms if overly aggressive initial dosing occurred.
9. Complications
Recurrent respiratory depression after naloxone wears off (duration mismatch), precipitated acute withdrawal from overly aggressive naloxone dosing, aspiration, noncardiogenic pulmonary edema, seizures (specific agents), arrhythmia (loperamide and other atypical agents), missed co-ingestant toxicity. Prevention: naloxone titrated to minimum effective dose/endpoint rather than full reversal, extended monitoring duration appropriate to the specific opioid's half-life, co-ingestant screening. Rescue: repeat naloxone dosing or infusion, mechanical ventilation for refractory cases, benzodiazepines for seizures, standard arrhythmia management for loperamide/atypical agent cardiotoxicity.
10. Escalation & De-escalation
Escalate: recurrent respiratory depression as naloxone wears off -> repeat dosing or initiate continuous infusion at two-thirds effective bolus dose/hour; refractory respiratory failure despite naloxone -> mechanical ventilation.
De-escalate: sustained adequate respiratory status off naloxone through the appropriate monitoring window for the specific opioid involved -> discontinue monitoring, transition to psychiatric/addiction medicine evaluation.
11. ICU Discharge Criteria
Sustained adequate respiratory status without naloxone support through an appropriate observation window (extended for long-acting opioids), no evidence of co-ingestant toxicity requiring ongoing treatment, no cardiac arrhythmia concern, psychiatric/addiction medicine evaluation completed, harm-reduction counseling and naloxone take-home kit provided where applicable per institutional protocol.
12. Documentation & Medicolegal Checklist
13. Key Guidelines
Boyer EW. Management of opioid analgesic overdose. N Engl J Med. 2012;367(2):146-155.
14. Controversies
Optimal naloxone dosing strategy in the fentanyl/fentanyl-analog era (higher initial doses vs careful titration) is an evolving area given these agents' potency and the resulting tension between adequate reversal and precipitating severe withdrawal. The role and threshold for continuous naloxone infusion vs repeated bolus dosing lacks strong comparative trial data, leaving practice largely expert-opinion and pharmacist/toxicologist-guided.
15. References
- Toxicology (Opioids section). Washington Manual of Critical Care, 4th ed, 2025 (Ch. 36).
- Boyer EW. Management of opioid analgesic overdose. N Engl J Med. 2012;367(2):146-155.
- Singh O, et al. General Poisoning Management. ICU Protocols: A Step-wise Approach, 2nd ed. Springer; 2020 (Ch. 14).
See also: Organophosphate Poisoning (Toxicology System) for the shared general poisoned-patient framework, toxidrome table, and ICU admission criteria; Acute Liver Failure (GI & Hepatology System) for acetaminophen co-ingestant management.